Publications by authors named "E M Penas-Lledo"
The CYP2C19 enzyme is implicated in the metabolism of several clinically used drugs. Its phenotype is usually predicted by genotyping and indicates the expected enzymatic activity for each patient. However, with a few exceptions, genotyping has not resulted in a reliable prediction of the metabolizer status, since most of the evidence currently available for this prediction comes from research into populations of predominantly European ancestry.
View Article and Find Full Text PDFArticle Synopsis
- Research highlights the importance of studying pharmacogenetic variability in drug responses, especially in diverse populations like those from the Dominican Republic.
- The study analyzed 197 healthy volunteers' genetic ancestry and found unique CYP allele frequencies that reflect a mix of European, Native American, and African ancestries, with implications for drug metabolism.
- Findings suggest the need for ethnicity-aware pharmacogenetic guidelines to ensure personalized medicine is accessible and effective for all populations.
The Ibero-American Network of Pharmacogenetics and Pharmacogenomics (RIBEF) studies Latin American populations to benefit from the implementation of personalized medicine. Since 2006, it has studied ethnicity to apply pharmacogenetics knowledge in autochthonous populations of Latin America, considering ancestral medicine. The meeting 'Pharmacogenetics: ethnicity, Treatment and Health in Latin American Populations' was held in Mexico City, Mexico, and presented the relevance of RIBEF collaboration with Latin American researchers and the governments of Mexico, Spain and the Autonomous Community of Extremadura.
View Article and Find Full Text PDF